You are here

Features

Features section

Peugeot 301 1.6 VTI: Common sense compact saloon

By - Nov 08,2021 - Last updated at Nov 08,2021

Photos courtesy of Peugeot

A well devised and executed car first launched in late 2012, the Peugeot 301 was the French manufacturer’s foray into strengthening its position in emerging markets, in light of the growing popularity of Korean manufacturers in the post global recession era. Comfortable, sensible, uncomplicated and rugged yet elegant, refined and spacious, the 301 has been going strong since.

Manufactured in Spain and several emerging markets, the 301 was revised for the 2017 model year, and remains a refreshingly honest, user-friendly and affordable compact saloon, as its production run continues.

Restrained refresh

Built with common sense engineering and well packaged in a more traditionally elegant saloon format, as often favoured over hatchbacks in many developing markets, the Peugeot 301’s design and finish, however, have a more stylishly upmarket and somewhat conservative air than many rivals designed with faddish designs and which are too obviously built to a cost. A standout in its highly competitive compact saloon segment, the revised and face-lifted 301 received a mild design refresh, updated infotainment system and a new and improved 6-speed automatic gearbox option.

The 301’s most noticeable visual changes include a narrower grille with re-positioned emblem and the deletion of its predecessor’s upper headlight kink, in favour of a moodier, more strongly browed design with more assertive lighting elements. Along with revised bumpers and bonnet, the face-lifted 301 looks fresher and more elegantly mature, with greater horizontal emphasis. At the rear, a revised light pattern similarly looks better integrated. Meanwhile, its roofline, strong side crease-line, comparatively spacious head, leg and shoulder room, and voluminous and expandable 506-litre boot are unchanged.

Capable comfort

Developed with sensible comfort, cost-efficiency and affordability in mind, the 301 rides on moderate 195/60R16 tyres, which visually well-fill its wheel-arches, but also offer durability and comfort over rougher surfacing, and help with steering feel and accuracy. MacPherson strut front and torsion beam rear suspension design is meanwhile effective and uncomplicated, and generous near crossover SUV-like 165mm ground clearance is well suited for poorly paved, unpaved and rutted developing market roads. A forgiving ride, the 301 is a comfortable long distance driver and practical, user-friendly day car.

Built as an effective and affordable daily drive, the 301 1.6 VTI’s use of Peugeot’s well-proven 1.6-litre 16-valve DOHC conventional multi-point injection engine — instead pricier and more sensitive direct injection or turbo technology — is well-suited for developing markets. Durable, smooth and fuel efficient, the 301 1.6 VTI’s engine develops 113BHP at 6,050rpm and 111lb/ft at 4,000rpm. Its delivery is progressive and smooth, with good low-end response, mid-range versatility and willing top-end. Meanwhile, restrained 1,185kg mass helps efficiency and performance, and allows for the use of lighter, less costly components throughout.

Refined ride

Gaining a 6-speed automatic gearbox in place of an outgoing 4-speed auto, the revised 301’s broader range of ratios improves low- and mid-range on the move flexibility, highway refinement and real world efficiency. A smoother and more consistent drive, the revised 301’s new slick shifting gearbox reduces the necessity for aggressive kickdown shifts when overtaking or on inclines. In terms of performance and consumption, the revised 301 is estimated to retain or slightly improve on its predecessor, with approximate 10.5-second 0-100km/h acceleration, 188km/h top speed and 7.3l/100km combined fuel efficiency.

Finding a good compromise between stability and responsiveness and comfort and handling the 301 feels dynamically adept in most circumstances. It is refined and reassuring on highways and sweeping bends, but is sufficiently agile through narrow winding lanes, and well manoeuvrable in town, with good visibility to place it easily on road. Similarly, its steering wheel also finds a good compromise between high speed damping, low speed lightness and decent feel, feedback and turning speed, including 3.15-turns lock-to-lock. Meanwhile, braking is reassuring and responsive, with ABS and emergency brake assistance.

Classy quarter

Tidy into corners, the 301 well controls body lean for a comfortably sprung and comparatively high riding saloon, while its’ steering relays good feel for road surface, grip limit and position. Supple and designed for demanding conditions and as a first new family car, the 301 forgivingly dispatches lumps and bumps, while body roll is not overly evident through corners. With decent vertical control and ground clearance, the 301 rides comfortably yet feels settled over crests and dips, as it fluently irons out road imperfections.

Classy in design and ambiance for a car expected to perform in tough conditions, the 301 features comparatively good quality plastics and textures in prominent places, including its gear lever, dials and sporty contoured steering wheel, while layouts and controls are intuitive and user-friendly. Meanwhile, cost-cutting components are more discreet, and include centre console electric window buttons. Well-equipped for an affordable world car, the 301 features particularly effective heating and air conditioning, and now even includes an Android Auto and Apple Carplay enabled 7-inch infotainment screen system. 

TECHNICAL SPECIFICATIONS

  • Engine: 1.6-litre, 16-valve DOHC, transverse 4-cylinders 
  • Bore x stroke: 78.5 x 82mm
  • Compression ratio: 11:1
  • Gearbox: 6-speed auto, front-wheel-drive
  • Power, BHP (PS) [kW]: 113.5 (115) [85] @6,050rpm
  • Specific power: 71.5BHP/litre
  • Torque, lb/ft (Nm): 111 (150) @4,000rpm
  • Specific torque: 94.5 Nm/litre
  • 0-100km/h: 10.5-seconds (estimate)
  • Standing km: 32-seconds (estimate)
  • Top speed: 188km/h (estimate)
  • CO2 emissions: 154g/km
  • Fuel consumption, combined: 7.3-litres/100km (estimate)
  • Fuel capacity: 50-litres
  • Height: 1,466mm
  • Width: 1,748mm
  • Length: 4,445mm
  • Wheelbase: 2,652mm
  • Tread, F/R: 1,501/1,478mm
  • Overhang, F/R: 819/974mm
  • Ground clearance: 165mm
  • Aerodynamic drag coefficient: 0.32 (estimate)
  • Headroom, F/R: 1,091/849mm
  • Shoulder room, F/R: 1,380/1,359mm
  • Luggage capacity, min/max: 506-/1,332-litres
  • Kerb weight: 1,185kg (estimate)
  • Suspension, F/R: MacPherson struts/torsion beam
  • Steering: Electric-assisted rack and pinion
  • Turning circle: 10.7-metres
  • Lock-to-lock: 3.15-turns
  • Brakes, F/R: Ventilated discs/drums
  • Tyres: 195/55R16

 

Take a breath!

By - Nov 07,2021 - Last updated at Nov 07,2021

Photo courtesy of Family Flavours magazine

By Haneen Mas’oud
Clinical Psychologist

 

How do you deal with different stressful situations? Here are healthy distractions to control and manage the physical (headache, chest heaviness, muscle tension) and psychological symptoms (racing negative thoughts, overwhelming emotions, anxiety, depression) of stress.

Remember, not every exercise or tool suits everyone. However, you will want to try out these simple breathing exercises to see if they work for you. 

If this is your first time trying breathing exercises, you may experience dizziness and uncomfortable feelings. If you keep feeling unwell, then these exercises are not for you. Please consult with your doctor before attempting any.

 

Alternate nostril breathing

In this exercise, you will need to:

1. Place your index and middle finger (right hand) on your forehead

2. Close your right nostril with your thumb and take a slow breath from your left nostril

3. Close your left nostril with your ring finger and open your right nostril by removing the thumb

4. Breathe out (exhale) through your right nostril and then inhale from it

5. Close the right nostril and exhale from the left one. Then take a breath from the same nostril

6. Continue switching between nostrils the same way mentioned above and repeat the cycle as much as needed

 

Box Breathing

You can draw a square and practice on paper first and then you can do it without paper.

1. Use your finger to guide you around the box you drew (optional)

2. Start by inhaling from your nose for four seconds

3. Hold your breath for four seconds

4. Exhale from your mouth for four seconds

5. Hold again and repeat the cycle as often as needed

 

Progressive Relaxation Technique

This exercise involves tensing a group of your body muscles and then relaxing them to release stress.

1. Start with the pose of Charles Atlas (see image) where you curl your right and left fists and simultaneously tighten your biceps and forearms, and then relax (you can say to yourself: Relax, my body is relaxed, I’m relaxed)

2. Roll your head and roll your neck clockwise in a complete circle, and repeat in the opposite direction, and relax

3. Move to the face muscles by wrinkling the forehead, with your mouth opened and shoulders hunched and then relax

4. Take a deep breath with your shoulders arched towards the back and hold for three seconds and exhale. Then take another deep breath pushing your stomach out, hold for three seconds and exhale (relax)

5. For the lower part of your body, straighten your legs by directing your toes toward your face, hold for three to four seconds and then relax (your calves, thighs and buttocks will be engaged here)

 

Eye Relaxation (palming)

1. Close your eyes placing your palms over them, do not put much pressure on your eyes; you should see a black colour and maybe other colours or images, shift your focus to the black colour only

2. Spend two minutes if you feel comfortable focusing on the black colour

3. Lower your hands and slowly open your eyes and notice your transition from tension to relaxation

Some small tension releasers can also be helpful, such as sighing and yawning. You can sigh deeply, feeling how the air rushes out of your lungs. Also, you can open your mouth while stretching your arms above your head and yawn as loudly as you can. Repeat as needed. 

So, with these simple techniques, I hope that you enjoy the art of relaxing!

 

Reprinted with permission from Family Flavours magazine

The risks of being human

By - Nov 07,2021 - Last updated at Nov 07,2021

Transcendent Kingdom
Yaa Gyasi
New York: Vintage Books, 2021
Pp. 290

 

“Transcendent Kingdom” is Ghanaian-American author Yaa Gyasi’s second novel. Except for the emotionally-charged writing and intriguing characters, it could not be more different from her first novel. “Homegoing” was of epic proportions, rotating between Africa and the US to trace the lives of an African family and their descendants from the 1700s onwards, and chronicling the long-lasting, devastating effects of the slave trade.

In contrast, “Transcendent Kingdom” is set entirely in the present day and focuses on the interior lives of the main characters. Racism is more subtly depicted in “Transcendent Kingdom” but is still a pervasive, negative factor in Black people’s lives, though it may not seem like the main problem at first. Many other issues are at play — science, religion and philosophy of life.

The narrator, Gifty, is a six-year PhD candidate in neuroscience at the Stanford University School of Medicine. She is painfully aware that her research is not of interest to most people, but in addition to its academic value, it is vital to her understanding of herself, her family and the world. Family is the key world here. The child of immigrants from Ghana who settled in Alabama, Gifty once had a father and brother. But her mother proved to be the only one with the excessive work ethic and psychological fortitude required to work overtime and underpaid as required to make it in America. Or so it seemed. First, Gifty’s father returned to Ghana. Then, even more painful, her popular, athletic brother fell victim to the opioid epidemic and died of a heroin overdose. With the family reduced from four to two, her mother’s fortitude cracked and she succumbed to a deep depression.

Though raised in the Pentecostal Church where her mother was a devotee, Gifty became more inclined towards science as she matured. She was nearing the completion of her research when her mother’s break-down reoccurred. This is the now-time of the novel and the rest of the story is told in flashbacks — Gifty’s childhood, how she was sent to Ghana for the summer when her mother suffered her first breakdown, how she tailored her academic path to her family concerns, leading to research in the neural circuits of reward-seeking behaviour, explored via experiments with rats. Through this research, she hopes to understand her brother’s addiction and her mother’s depression. At the same time, Gifty begins to doubt that science alone can heal people, leaving the door open to an undefined spiritual dimension in her life and the novel.

Gifty is fascinated with the brain, the organ that allows Homo sapiens to believe that they have transcended their Kingdom: “That belief, that transcendence, was held within this organ itself. Infinite, unknowable, soulful, perhaps even magical. I had traded the Pentecostalism of my childhood for this new religion, this new quest, knowing that I would never fully know.” (p. 21)

Within this family story, Gyasi covers a range of contemporary realities. Her mother works as a caregiver, typical employment for female immigrants and people of colour in the US today. For years, she cares for an old white man who feels no compunction about directing racist slurs at her. Such work is almost synonymous with night shifts, often leading to addiction to sleeping pills. This is a new type of immigrant story, being set mostly in the semi-rural American South where Gifty (and the author) grew up, whereas earlier immigrant stories were usually urban-based. Gyasi also raises current, hotly-debated health issues via Gifty’s medical insight: “Most people’s immune systems are highly capable and efficient. Overprescription is a huge problem in this country, and if we don’t take charge of our own health, we’re susceptible to all kinds of manipulation from pharmaceutical companies who profit off of keeping us ill… “(p. 124)

Questions of identity, culture and assimilation are integral to the plot, playing a role in the demise of both Gifty’s mother and brother, and in Gifty’s own vacillation between science and faith. In the case of her mother, who spoke three languages, these issues are particularly salient. As she descended into a helpless depression, it was shocking for Gifty to see how her mother, whom she had regarded as strong, even fearsome, “shrank down to someone I could hardly recognise. And I don’t think she did this because she wanted to. I think, rather, that she just never figured out how to translate who she really was into this new language”. (p. 136)

From the problems of the immigrant experience, Gifty goes on to pose existential questions about human beings as such: “The only animal in the known world that is willing to try something new, fun, pointless, dangerous, thrilling, stupid, even if we might die in the trying.” (p. 243)

Gyasi’s characters are impetuous, inconsistent, full of contradictions and exasperating, which makes it hard to anticipate the conclusion. One keeps on turning pages to find out if Gifty can reconcile herself to the human condition that she so poignantly describes. Once again, Gyasi has created a beautifully-written, thought-provoking novel, and shown herself to be a versatile storyteller. She restores the humanity and dignity of immigrants by showing that they face the full range of human dilemmas, not only the special problems of the outsider.

Scientists discover cause of Alzheimer’s progression in brain

By - Nov 07,2021 - Last updated at Nov 07,2021

By Issam Ahmed
Agence France-Presse

WASHINGTON — Toxic protein clusters thought responsible for the cognitive decline associated with Alzheimer’s disease reach different regions of the brain early and then accumulate over the course of decades, according to a recent study.

The research, published in Science Advances, is the first to use human data to quantify the speed of the molecular processes leading to the neurodegenerative condition and could eventually have important implications for how scientists design treatments.

It also upends a long-held theory that said Alzheimer’s progression was mainly caused by clusters spreading between different brain regions in a “chain reaction”, as has been found in mice and was thought true of people too.

“Two things came together that really made this work possible,” Georg Meisl, a chemist at the University of Cambridge and the paper’s lead author told AFP. 

“One is very detailed data from PET [scans] and various different data sets we’ve put together, and the other thing is the mathematical models we’ve been developing over the past ten years.”

Specifically, the researchers used close to 400 post-mortem brain samples from Alzheimer’s as well as 100 positron emission tomography scans from people living with the disease to track the aggregation of tau, one of two key proteins implicated in the condition.

In Alzheimer’s disease, tau and another protein called amyloid-beta build up into tangles and plaques — known together as aggregates — that cause brain cells to die and lead to brain shrinkage.

This in turn results in memory loss, personality changes and inability to carry out daily functions associated with the condition, which affects 44 million people globally.

Exponential growth

Past research, mainly performed on animals, suggested the aggregates form in one region then spread throughout the brain, much like how cancer spreads.

The new study suggests that while such spread may occur, it’s not in fact the main driver of disease progression.

“Once we have these seeds, little bits of aggregate throughout the brain, they just multiply and that process controls the speed,” said Meisl.

An analogy from the COVID pandemic is how travel bans between nations generally proved ineffective at stopping the spread of the virus, because it was already replicating within the countries trying to keep it out.

The team was also able to determine the time it takes the aggregates to double in number — roughly five years. That is an “encouraging” figure, said Meisl, because it shows the brain’s neurons already are good at countering aggregates. 

“Maybe if we can make it just a tiny bit better we can significantly delay the onset of serious disease.”

Alzheimer’s disease is classified according to what are known as “Braak stages”, and the team found it took around 35 years to progress from stage three, when mild symptoms first become apparent, to stage six, the most advanced.

If aggregates roughly double over five years, then over 35 years they would have risen 128-fold. This exponential growth “explains why it takes so long to develop and then people tend to get worse quite quickly”, said Meisl.

The team next intends to investigate frontotemporal dementia and traumatic brain injury using the same methods. 

“Tau is a culprit protein in a number of different dementias, and it would make sense to explore how this protein spreads in diseases like frontotemporal dementia,” Sara Imarisio, of Alzheimer’s Research UK, said in a statement.

“Hopefully this study and others like it will help focus the development of future treatments that target tau, so [they] have a better chance of slowing the disease processes themselves and have benefit for people with dementia.”

The era of anti-COVID pills begins

By - Nov 07,2021 - Last updated at Nov 07,2021

Merck’s molnupiravir pill works by decreasing the ability of a virus to replicate, thereby slowing down the disease (AFP photo)

PARIS — What if a simple pill could help heal from COVID-19?

US pharma giants Merck and Pfizer have announced encouraging results for oral drugs, while an anti-depressant has also shown promise in what could open up a new chapter in the fight against the pandemic.

What are these treatments?

They are pills taken orally as soon as the first symptoms of COVID-19 appear, to avoid serious forms of the illness, and therefore hospitalisation.

This form of treatment has been sought since the start of the global health crisis.

After months of research, Merck and Pfizer say they have reached that elusive goal.

Early October, Merck said it was seeking authorisation in the United States for its pill molnupiravir, and Pfizer followed suit on Friday with paxlovid.

They are both anti-virals that act by reducing the virus’s ability to replicate, slowing down the disease.

Both companies say clinical trials showed a strong reduction in the risk of hospitalisation.

Those who took molnupiravir saw that risk diminish by 50 per cent and those who took paxlovid by nearly 90 per cent, although direct comparisons of these efficacy rates should be avoided because of the different study protocols.

An anti-depressant which is already available to the public, fluvoxamine, has also shown encouraging results in preventing serious forms of COVID-19, according to a study published in October by Brazilian researchers in the Lancet Global Health journal.

Why are they important?

If the efficacy of these drugs is confirmed, it will be a major step forward in the fight against COVID-19.

They would add to vaccines to bolster the world’s therapeutic arsenal against the virus.

Treatments already exist, mostly in the form of synthetic antibodies.

But these drugs, which usually target those who already have severe forms of the disease, are injected and therefore more difficult to administer.

A pill can be quickly prescribed to a patient who will then take it easily at home.

Merck and Pfizer’s treatments, which so far have not shown many side effects, would entail taking around 10 doses over five days.

“The success of these antivirals potentially marks a new era in our ability to prevent the severe consequences of SARS-CoV2 infection,” British virologist Stephen Griffin told the Science Media Centre.

What limitations ?

It is difficult so far to properly evaluate Merck and Pfizer’s treatments given both groups have only published statements and have not made the data of their clinical trials available.

French infectious diseases specialist Karine Lacombe warned in September that these types of announcements should be treated with “caution” until the studies can be scrutinised.

She pointed out that these treatments represent a “potentially enormous” market for pharmaceutical groups.

Nevertheless, some elements indicate that Merck and Pfizer are not making empty promises.

For one, they both stopped their clinical trials earlier than expected as the results were so strong, with the okay of independent monitoring committees.

Where fluvoxamine is concerned, the data is available but is not without criticism.

Several researchers have complained that the authors did not just limit themselves to evaluating the frequency of hospitalisations, but also assessed the frequency of prolonged emergency room stays.

This, they say, complicated the interpretation of data.

When? And how much?

Merck’s molnupiravir has already been approved in the United Kingdom where health authorities on Thursday gave their green light to its use in patients at risk of developing a serious form of the illness, such as the elderly, obese people, or those suffering from diabetes.

US and EU health authorities are also urgently reviewing the drug.

The European Medicines Agency promised on Thursday to “accelerate” proceedings, without giving a firm date.

Several countries have already ordered stocks of molnupiravir, such as the United States, with 1.7 million courses of the drug.

The US order gives an idea of the steep price of the drug.

It comes to $1.2 billion, which equates to around $700 for a five-day course.

As for Pfizer, while it has not outlined a price for paxlovid, it has promised it will be “affordable” and subject to a tiered pricing approach based on the income level of countries.

Russian art trove and its tortured history comes to Paris

Nov 04,2021 - Last updated at Nov 04,2021

Visitors look at paintings by French painter Pierre Bonnard during a press visit of the exhibition ‘The Morozov Collection — Modern art icons’ at the Fondation Louis Vuitton in Paris on September 15 (AFP photo)

 

By Frédérique Pris
Agence France-Presse

PARIS — The line-up at the Louis Vuitton Foundation's new exhibition in Paris reads like a who's who of artistic giants from the Belle Epoque: Van Gogh, Picasso, Monet, Matisse, Cezanne... 

What is most surprising is that they all come from one collection — a pair of Russian brothers from the late 19th century who just happened to have an absurdly good eye for who would become the geniuses of their generation. 

Mikhail and Ivan Morozov, born into a textile dynasty in the 1870s, went to Paris and came back with treasures — Manet, Renoir, Toulouse-Lautrec, Rodin — that were barely recognised as such at the time.

Indeed, Mikhail was the first to bring Van Gogh and Gauguin paintings to Russia.

Some 200 of their portraits, sculptures and photographs are showing at the Louis Vuitton Foundation, on loan from Russian museums. 

They had a torturous route through the 20th century — surviving revolution and years hidden away after World War II. 

The new exhibition in Paris has also had its troubles, delayed three times by the pandemic and finally starting a year late. 

But it promises to be another successful borrowing from the Russian archives, following the museum's mammoth success with the Shchukin exhibition in 2016-17. 

That show — a similar treasure trove compiled by a contemporary of the Morozov brothers — drew 1.29 million visitors to the Louis Vuitton Foundation, which it said made it the most successful show in France for half a century.

No doubt much attention will go to the work by Van Gogh, who gets a room apart for his little-known late work "Prisoners Exercising", featuring a familiar ginger-haired figure staring at the viewer, a self-portrait snuck into the grim setting. 

Exile and recovery

Mikhail Morozov's high living brought him an early death at 33, though he had already amassed 39 masterpieces. 

His brother Ivan picked up the baton and became one of the world's great collectors.

But it all came crashing down with the Communist revolution of 1917 in Russia.

Ivan was reduced to being "assistant curator" of his own collection as his home became a state museum, before soon fleeing into exile. 

Later, the paintings were sent into hiding in the Ural mountains when the Nazis invaded in 1941. 

They spent years out there, fairly well preserved by temperatures that often fell to minus-40 degrees, and it was only in the late 1950s that the Soviet government dug them out and sent them to the Tretyakov, Pushkin and Hermitage collections.

"The Morozov Collection: Icons Of Modern Art" is at the Louis Vuitton Foundation until February 22.

At the ‘Human Library’, everyone is an open book

By - Nov 03,2021 - Last updated at Nov 03,2021

Photo courtesy of wordpress.com

COPENHAGEN — At the “Human Library”, you can “loan” a person to tell you their life story, an original concept born in Denmark that is designed to challenge prejudice and which has spread around the world.

Iben — a quiet 46-year-old sexual abuse victim with mental health issues who doesn’t give out her last name — is one of eight “books” curious people can loan on this autumn day in Copenhagen.

For 30 minutes, you can ask anything you want, either one-on-one or in a small group.

“The Human Library is a safe space where we can explore diversity, learn about ways in which we’re different from each other, and engage with people we normally would never meet... and challenge your unconscious bias,” explains Ronni Abergel, the project’s garrulous initiator.

He created the living library in 2000 during the Roskilde music festival and went on to build a non-profit organisation.

The concept has since found its way into more than 70 countries.

“A reading truly is a conversation,” says Abergel.

“I’m going to take a few minutes to explain my topic, my background, and to make sure that you can ask me anything about being HIV [positive] or disabled, or transgender, or a refugee or Jewish or Muslim, or whatever my topic may be.”

 

Blank pages

 

In most cases the conversations flow freely, typically held in a calm environment like a city library, a meeting room, or as today, in the garden of the Human Library’s premises.

“Sometimes people ask a lot and the conversation flows. But sometimes I maybe need to tell them a little bit more, ask my readers questions in order for them to reflect or ask new questions,” says Anders Fransen, a 36-year-old blind and hearing impaired “book”.

People are encouraged “to ask really difficult questions”, Abergel says, stressing that nothing is off limits, no matter how sensitive the subject may be.

People who loan Iben can choose between three of her oral books: Sexual abuse victim, living with borderline personality disorder or severe post-traumatic stress disorder.

She has on occasion refused to answer questions.

“I have said that that page wasn’t written yet. So they just smiled and said okay,” she recalls.

But she’s never had a bad experience in her four years.

“All my readings are different,” and they’ve evolved over the years, she says.

“When I started, I was in a totally different place... I’ve been working on myself for years.”

“It’s such a gift [being] a book, you can self-reflect.”

Fransen says he’s proud to have helped people develop how they think about handicaps.

After a recent “reading” with some eighth graders, he overheard them talking to their friends.

“They were saying ‘hey, this guy is a cool guy, he has a cool story to tell.’ So I made an impression on them,” he smiles.

 

‘Neutral learning space’

 

“Loanees”  come away with powerful experiences too. 

“All the responses we’re getting indicate that it’s a high impact experience,” Abergel says.

He was recently contacted by a reader who borrowed a human book in 2004. 

“She was telling us about the impact [the book had] on her view on Muslims... And she had used that information in the 17 years that have passed. So that has been to the benefit of the community, her and other people of Muslim background.”

In an increasingly polarised world, Abergel wants his initiative to help people become “less apprehensive, more open, more understanding and accepting of your right to be different”.

But, he insists, the organisation is not about promoting diversity or combating prejudice.

“We run a neutral learning space where there is an opportunity for you to engage, learn about yourself and other groups,” he says.

“What you learn and what you do with your learning is entirely in your hands.”

One of those loaning a book is 41-year-old Karem.

“To see the person and listen to him or her and see the perspective, the whole story that is almost unfolding in front of you” is “very touching”, he says.

“It lets people see that at the end of the day we are a lot of titles, but the same flesh and blood and bones.”

 

Needle-free vaccine patches coming soon, say researchers and makers

By - Nov 02,2021 - Last updated at Nov 02,2021

Photo courtesy of unc.edu

WASHINGTON — Effective vaccines, without a needle: Since the start of the COVID pandemic, researchers have doubled down on efforts to create patches that deliver life-saving drugs painlessly to the skin, a development that could revolutionise medicine.

The technique could help save children’s tears at doctors’ offices, and help people who have a phobia of syringes.

Beyond that, skin patches could assist with distribution efforts, because they don’t have cold-chain requirements — and might even heighten vaccine efficacy.

A new mouse study in the area, published in the journal Science Advances, showed promising results.

The Australian-US team used patches measuring one square centimetre that were dotted with more than 5,000 microscopic spikes, “so tiny you can’t actually see them”, David Muller, a virologist at the University of Queensland and co-author of the paper, told AFP.

These tips have been coated with an experimental vaccine, and the patch is clicked on with an applicator that resembles a hockey puck. “It’s like you get a good flick on the skin,” said Muller.

The researchers used a so-called “subunit” vaccine that reproduces the spikes that dot the surface of the coronavirus.

Mice were injected either via the patch over the course of two minutes, or with a syringe.

The immune systems of those who got the patch produced high levels of neutralising antibodies after two doses, including in their lungs, vital to stopping COVID, and the patches outperformed syringes. 

The researchers also found that a sub-group of mice, who were given only one dose of vaccine containing an additional substance called an adjuvant used to spur immune response, “didn’t get sick at all”, said Muller.

 

Easy to apply

 

What makes them more effective?

Vaccines are normally injected into our muscles, but muscle tissue doesn’t contain very many immune cells needed to react to the drug, explained Muller.

In addition, the tiny spikes cause localised skin death, which alerts the body to a problem and triggers a greater immune response. 

For the scientist, the logistical advantages couldn’t be clearer. 

First, when dry-coated on a patch, the vaccine is stable for at least 30 days at 25ºC and one week at 40ºC, compared to a few hours at room temperature for the Moderna and Pfizer vaccines.

This offers a major advantage particularly for developing countries.

Second, “it’s very simple to use”, said Muller. “You don’t necessarily need highly trained medical professionals to deliver it.”

Burak Ozdoganlar, a professor of engineering at Carnegie Mellon University in the US city of Pittsburgh, has also been working on the technology since 2007.

He sees yet another advantage: “Less amount of vaccine delivered precisely to skin can activate an immune response similar to intramuscular injection,” he told AFP. It’s an important factor as the developing world struggles to procure enough COVID vaccine.

Ozdoganlar can produce around 300-400 patches a day in his lab, but hasn’t been able to test them out on mRNA vaccines, which have come to the fore during the pandemic, because he hasn’t been authorised by Pfizer or Moderna.

 

‘The future’

 

The patch used in the study published on Friday was made by Australian company Vaxxas, which is the furthest along. Human trials are planned from April. 

Two other American companies are also part of the race: Micron Biomedical and Vaxess.

The latter, founded in 2013 and based in Massachusetts, is working on a slightly different type of patch, with microneedles that dissolve in the skin.

They say this approach has the benefit of requiring fewer spikes per patch — just 121 — made of a protein polymer that is biocompatible.

“We’re working on a seasonal COVID and flu combination product that will be mailed directly to patients’ homes, for self-administration,” CEO Michael Schrader told AFP.

The COVID vaccine they are using is produced by the company Medigen, already authorised in Taiwan. 

Vaxess has just opened a factory near Boston, with funding from the US National Institutes for Health. They aim to produce enough patches to vaccinate 2,000 to 3,000 people in clinical trials, which are to be launched next summer.

The main challenge right now is production, with no manufacturers yet able to make enough patches en masse.

“If you want to launch a vaccine you have to produce hundreds of millions,” said Schrader. “We do not have that scale as of today — no one really has that scale.”

But the pandemic has given a push to the nascent industry, which is now attracting more investors, he added.

“This is the future, in my opinion, it is inevitable,” said Schrader. “I think you’re going to see over the next 10 years, this [will] pretty dramatically reshape the way that we get vaccines around the world.”

 

Drifting into trouble: Tiny ocean creatures with a global impact

By - Nov 01,2021 - Last updated at Nov 01,2021

By Kelly Macnamara
Agence France-Presse

PLYMOUTH, United Kingdom — The strange metal box hauled from the waves and onto the ship’s deck looks like a spaceship fished from a child’s imagination. 

But when scientist Clare Ostle opens it up and draws out the silk scrolls inside, she is looking for the telltale green glow from some of the most important creatures on Earth: plankton.

This is a Continuous Plankton Recorder, torpedo-like devices that for 90 years have been towed by merchant vessels and fishing boats on a vast network of routes.

They help researchers better understand the ocean by collecting some of its smallest inhabitants.

What they have seen is that as climate change heats the seas, plankton are on the move — with potentially profound consequences for both ocean life and humans.

Plankton — organisms carried on the tides — are the foundation of the marine food web.

But they are also part of an intricately balanced system that helps keep us all alive.

As well as helping produce much of the oxygen we breathe, they are a crucial part of the global carbon cycle.

“The big thing that we’re seeing is warming,” Ostle, coordinator of the Pacific CPR Survey, tells AFP as she demonstrates the plankton recorder off the coast of Plymouth in Britain.

The CPR Survey has documented a decisive shift of plankton towards both the poles in recent decades, as ocean currents change and many marine animals head for cooler areas.

Smaller warm water plankton are also replacing more nutritious cold water ones, often also with differing seasonal cycles, meaning the species that feed on them need to adapt or move too. 

“The big worry is when change happens so quickly that the ecosystem can’t recover,” says Ostle, adding that dramatic temperature spikes can lead “whole fisheries to collapse”.

With nearly half of humanity reliant on fish for some 20 per cent of their animal protein, this could be devastating.

Biological pump

Plankton is a catch-all term from the Greek for “drifting” and encompasses everything from photosynthesising bacteria many times smaller than the width of a human hair, to jellyfish with long trailing tendrils. 

There are two main types: Phytoplankton, diverse plant-like cells commonly called algae; and zooplankton, animals like krill and the larvae of fish, crabs and other marine creatures.

Phytoplankton photosynthesise using the sun’s rays to turn C02 into energy and oxygen. 

In fact, scientists estimate the seas produce around half the oxygen on Earth, and that is mostly thanks to phytoplankton.

They are also crucial to the ocean’s “biological carbon pump”, which helps the sea lock away at least a quarter of C02 emitted by burning fossil fuels.

While trees store carbon in wood and leaves, phytoplankton store it in their bodies.

It passes through the food web, with phytoplankton consumed by zooplankton which, in turn, are eaten by creatures from birds to whales.

“Pretty much everything you can think of in the sea at some stage of its life cycle will eat plankton,” says CPR Survey head David Johns.

When organic matter from dead plankton or their predators sinks to the ocean floor it takes carbon with it.

‘Escalating impacts’

But scientists warn that climate change has stressed the system, with ocean temperatures rising, fewer nutrients reaching the upper part of the ocean from the deep and increased levels of C02 acidifying seawater.

Climate change has “exposed ocean and coastal ecosystems to conditions that are unprecedented over centuries to millennia with consequences for ocean-dwelling plants and animals around the world”, says the UN’s Intergovernmental Panel on Climate Change (IPCC) in a leaked draft report on climate impacts, due to be published next year, which predicts “escalating impacts on marine life”.

While phytoplankton are relatively resilient and will likely continue to shift territory as the seas warm, the IPCC expects that deteriorating conditions in the oceans will ultimately lead to an overall decline this century.

Average global phytoplankton biomass — a measure of total weight or quantity — is predicted to fall by around 1.8 to 6 per cent, depending on the level of emissions.

But because of its outsized importance, even modest reductions can “amplify up the marine food web”, eventually leading to reductions in marine life by roughly 5 to 17 per cent.

There could also be “changes in carbon cycling and carbon sequestration, as our plankton community changes” with smaller plankton potentially drawing down less C02, says plankton ecologist Abigail McQuatters-Gollop of Plymouth University. 

As global leaders prepare to meet at a crucial UN summit on climate change, the issue is a stark example of how accelerating human impacts are destabilising intricate life-sustaining systems.

Thinking small

Tackling this is not as simple as planting trees, McQuatters-Gollop notes.

But fishing sustainably, reducing pollutants and curbing C02 emissions can all help improve ocean health. 

In the past, she says conservation has focused on “the big things, the cute things, or the things that are directly worth money” — like whales, turtles and cod. 

But all rely on plankton.

While this “blindness” could be because they are microscopic, people can see plankton traces at the beach — in foam on waves, or the nighttime twinkle of bioluminescence.

Or on the children’s television show “SpongeBob SquarePants”, whose character Plankton is “the most famous plankton out there”, says McQuatters-Gollop. 

And when they “bloom” in vast numbers, plankton are visible from space, turning the water a startling emerald, or creating Van Gogh swirls of milky blue, in seasonal displays critical for ocean life.

Like land plants, phytoplankton need nutrients like nitrates, phosphates and iron to grow. 

But they can have too much of a good thing: The runoff of nitrogen-rich fertilisers is blamed for creating harmful algae blooms, like the glutinous “sea snot” off Turkey’s coast this year. 

These can poison marine life or choke oxygen out of the water and may be exacerbated by warming, warns the IPCC.

Meanwhile, research published in Nature last month found that iron carried in smoke from huge 2019 and 2020 wildfires in Australia sparked a giant swell of phytoplankton thousands of kilometres away, which could have sucked up substantial amounts of C02. 

Blooms can be seeded by nutrients from sand storms or volcanic eruptions and it is these “natural processes” that have inspired David King, founder of the Centre for Climate Repair at Cambridge. 

King supports a hotly-debated idea to “fertilise” plankton blooms by sprinkling iron on the surface.

The theory is that this would not only help suck up more C02, but lead to a surge of ocean life, including eventually helping to increase whale populations that have been devastated by hunting.

More whales equals more whale poo, which is full of the nutrients plankton need to bloom, and King hopes could restore a “wonderful circular economy” in the seas.

Sea mysteries

Ocean organisms have been photosynthesising for billions of years — long before land plants. But we still have much to learn about them.

It was only in the 1980s that scientists named the planktonic bacteria prochlorococcus, now thought to be the most abundant photosynthesiser on the planet.

Some “drifters” it turns out can swim, while others are masters of communal living. 

Take the partnership between corals and plankton — it is so important that when it breaks due to warming the corals bleach.

Or Acantharea, a single cell shaped like a snowflake that can gather photosynthesising algae and manipulate them into an energy-generating “battery pack”, says Johan Decelle, of the French research institute CNRS and the University of Grenoble Alpes.

They have been “overlooked” because they dissolve in the chemicals used by scientists to preserve samples. 

To study plankton under a high-resolution electron microscope, Decelle used to collect samples at the French coast and drive for hours back to Grenoble with them in a special cool box. 

But this year he worked with the European Molecular Biology Laboratory on a pioneering project bringing high-tech freezing virtually onto the beach.

This enables the study of these delicate organisms as close as possible to their natural environment. 

By contrast, Continuous Plankton Recorders end up mashing their samples into “roadkill”, says Ostle.

But the value of the survey, which began in 1931 to understand how plankton affected herring stocks, comes from decades of data.

Ostle used CPR ships’ logs to show that “macroplastics” like shopping bags were already in the seas in the 1960s.

From the boat in Plymouth, the water appears calm as sunlight slides across its surface. But every drop is teeming with life.

“There’s just a whole galaxy of things going on under there,” Ostle says. 

Mercedes-Benz E350: Class act executive hybrid

By - Nov 01,2021 - Last updated at Nov 02,2021

Photos courtesy of Mercedes-Benz

Refreshed to more closely integrate with the German manufacturer’s revised design language as exemplified by new S- and C-Class models, Mercedes-Benz’s mid-size premium E-Class saloon returns to high tax markets in E350 guise.

Powered again by Mercedes’ high power 2-litre mild hybrid engine, the E350 is a quick, comfortable and conservatively styled hybrid executive saloon that appeals to drivers that might not be too enthusiastic about electrification, in that its design downplays its hybrid nature, while electric input serves to complement rather than subvert its combustion engine’s charms.

A curvier and more flowing design when first introduced in 2016, than its chunkier predecessor, the elegant, fluent and smoothly styled E-Class underwent a significant aesthetic face-lift last year for the current model year.

Bearing stronger resemblance to Mercedes’ newer models, the revised E-Class’s most obvious changes are at the rear, where it trades the outgoing model’s vertically-oriented diamond-like rear lights for more dramatically slim, prominently browed and horizontally-oriented lights, and includes slight bootlid and bumper changes at the rear, and in front to accommodate a new grille outline.

Athletic aesthetic

In front, the revised E-Class receives a new grille that is wider at the bottom, rather than the top, for a more dramatic and formal look, in addition to revised lights.

Driven with AMG Line exterior styling that aesthetically emphasises its athleticism, the revised E-Class features a new floating tri-pronged star emblem, flanked by single — rather than double — slats and a studded background grille pattern. In E350 guise, there are thankfully are no virtue-signaling badges, colours or design whimsies to allude to its hybrid drive-line, that might otherwise undermine its appeal.

With arcing lines, long snouty bonnet and grille, tapered rear, and flowing creases, the revised E-Class retains a fresh and contemporary aesthetic that is both elegant and sporty, especially with AMG appearance package. Meanwhile, and under its aggressive twin ridged bonnet, the driven E350 version is powered by a turbocharged direct injection 2-litre 4-cylinder engine developing 295BHP at 5,800-6,100rpm and 295lb/ft torque at 3,000-4,000rpm. Driving rear wheels through a smooth shifting 9-speed automatic gearbox, the E350 carries its 1,789kg mass through 0-100km/h in 5.9-seconds and onto an electronically-limited 250km/h maximum.

Punchy and prodigious

More eager in character than previous Mercedes turbo 2-litres, the E350’s delivery is more peaky and with narrower plateaus. The result is a seemingly punchier and more visceral driving experience, as power wells up quickly from mid-range. Though more linear, the E350 still offers plenty of early and mid-range torque for effortlessly muscular overtaking versatility and confidence on inclines. Quick-spooling from standstill, the E350’s delivery remains responsive to redline. Meanwhile, the E350’s combustion engine is subtly supplemented by its electric starter/generator 48V mild hybrid system, when necessary.

Producing 14BHP and 110lb/ft, the E350’s 48V hybrid system recovers kinetic braking energy and powers ancillary systems to reduce fuel consumption to 7.7l/100km, combined, and allows longer automatic coasting during driving and when coming to a stop. In helping drive the E350, the 48V system provides small supplementary bursts of power at up to 2,500rpm, and seemingly at full throttle. Well-integrated and near seamless, such assistance little interferes with driving fluency, with brief and rare moments of slight full throttle lift-off delay the only telltale sign of electrification.

Settled yet sporty

Stable, settled, refined and quiet on motorways with Mercedes’ near trademark ‘planted’ ride quality, the E350 is a smooth and natural long distance Autobahn cruncher. It is meanwhile at home in urban environments, where its cabin is comfortable and spacious — if not as generous in headroom as its immediate predecessor. With light, accurate steering and plenty of driver-assistance features like reversing sensors, 360° camera, parking assistance, blind spot assistance, and tight typically tight Mercedes turning circle, the E350 is meanwhile easily manoeuvrable in town for its class.

Lighter, and with more luggage volume, better drive-line integration and better weighting than the previous, more traditional hybrid E350e model with its heavy rear batteries, the 48V hybrid system E350 is a noticeable more agile and better handling car. Sportier than expected for an executive luxury express, the E350 feels light on its feet and alert through corners, with a quick, tidy and eager turn-in, while its steering and drive-line, and can be set-up for a meatier feel and more immediate responsiveness through the Dynamic Select driving mode menu.

Buttoned down and balanced

Well balanced, adjustable and agile through corners and with good body lean control, the E350 drives with a sporting sensibility through switchbacks. Committed and nimble into corners, the E350’s staggered low profile 245/40R19 front and 275/35R19 rear tyres provide good steering and braking properties. Rear grip is meanwhile reassuring when loading the outside tyres through a corner. However, it can have a more ‘drifty’ character on low traction tarmac, given its high torque output and subtly surging electric assistance, but upon which time, stability controls swiftly step in.

Intuitive in it chassis balance and steering weighting, the E350 is meanwhile settled and buttoned down in vertical movements, if slightly stiff over unevenly and overly choppy roads, or sudden sharp bumps and cracks. That said, ride quality is mostly smooth and forgiving, even with low profile tyres. Inside, it is refined and luxurious in ambiance, materials and design, with extensive safety features, mod cons and twin infotainment and configurable instrument screens. Driving position is comfortable, highly adjustable and supportive, while rear space is good for its class, and boot volume generous at 540-litres.

 

TECHNICAL SPECIFICATIONS

  • Engine: 2-litre, turbocharged, in-line 4-cylinders
  • Bore x stroke: 83 x 92mm
  • Compression ratio: 10.5:1
  • Valve-train: 16-valve, DOHC, variable timing, direct injection
  • Gearbox: 9-speed automatic, rear-wheel-drive
  • Ratios: 1st 5.35; 2nd 3.24; 3rd 2.25; 4th 1.64; 5th 1.21; 6th 1.0; 7th 0.86; 8th 0.72; 9th 0.6
  • Power, BHP (PS) [kW]: 295 (299) [220] @5,800-6,100rpm
  • Specific power: 148.1BHP/litre
  • Power-to-weight: 164.9BHP/tonne
  • Torque, lb/ft (Nm): 295 (400) @3,000-4,000rpm
  • Specific torque: 200.9Nm/litre
  • Torque-to-weight: 223.6Nm/tonne
  • Hybrid system: 48V starter/alternator
  • Electric power, BHP (PS) [kW]: 14 (14) [10]
  • Electric torque, lb/ft (Nm): 110 (150)
  • 0-100km/h: 5.9-seconds
  • Top speed: 250km/h (electronically limited)
  • Fuel economy, urban/extra-urban/combined: 10.3-/6.1-/7.7-litres/100km
  • CO2 emissions, combined: 175g/km
  • Fuel capacity: 66-litres
  • Length: 4,923mm
  • Wheelbase: 2939mm
  • Overhang, F/R: 841/1,143mm
  • Track, F/R: 1,616/1,619mm
  • Aerodynamic drag co-efficient: 0.26
  • Boot capacity: 540-litres
  • Kerb weight: 1,789kg (estimate)
  • Suspension: Multi-link
  • Steering: Electric-assisted rack & pinion
  • Turning circle: 11.6-metres
  • Brakes: Ventilated discs
  • Tyres, F/R: 245/40R19/275/35R19

Pages

Pages



Newsletter

Get top stories and blog posts emailed to you each day.

PDF